Immunopathogenesis and Immunogenetic Variants in COVID-19. 2022

Pakorn Sagulkoo, and Kitiporn Plaimas, and Apichat Suratanee, and Andrea Name Colado Simão, and Edna Maria Vissoci Reiche, and Michael Maes
Program in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok 10330, Thailand.

Coronavirus disease 2019 (COVID-19) continues to spread globally despite the discovery of vaccines. Many people die due to COVID-19 as a result of catastrophic consequences, such as acute respiratory distress syndrome, pulmonary embolism, and disseminated intravascular coagulation caused by a cytokine storm. Immunopathology and immunogenetic research may assist in diagnosing, predicting, and treating severe COVID-19 and the cytokine storm associated with COVID-19. This paper reviews the immunopathogenesis and immunogenetic variants that play a role in COVID-19. Although various immune-related genetic variants have been investigated in relation to severe COVID-19, the NOD-like receptor protein 3 (NLRP3) and interleukin 18 (IL-18) have not been assessed for their potential significance in the clinical outcome. Here, we a) summarize the current understanding of the immunogenetic etiology and pathophysiology of COVID-19 and the associated cytokine storm; and b) construct and analyze protein-protein interaction (PPI) networks (using enrichment and annotation analysis) based on the NLRP3 and IL18 variants and all genes, which were established in severe COVID-19. Our PPI network and enrichment analyses predict a) useful drug targets to prevent the onset of severe COVID-19, including key antiviral pathways such as Toll-Like-Receptor cascades, NOD-like receptor signaling, RIG-induction of interferon (IFN) α/β, and interleukin (IL)-1, IL-6, IL-12, IL-18, and tumor necrosis factor signaling; and b) SARS-CoV-2 innate immune evasion and the participation of MYD88 and MAVS in the pathophysiology of severe COVID-19. The PPI network genetic variants may be used to predict more severe COVID-19 outcomes, thereby opening the door for targeted preventive treatments.

UI MeSH Term Description Entries
D007125 Immunogenetics A subdiscipline of genetics which deals with the genetic basis of the immune response (IMMUNITY). Immunogenetic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071199 NLR Family, Pyrin Domain-Containing 3 Protein An NLR protein that contains an N-terminal PYRIN DOMAIN and ATP-binding site and 9 C-terminal LEUCINE-rich repeats; it is expressed primarily by MACROPHAGES. It is a core component of the INFLAMMASOME and directs its assembly in response to pathogen infection and damage-associated stimuli. Mutations in the NLRP3 gene are associated with FAMILIAL COLD AUTOINFLAMMATORY SYNDROME. Cold Autoinflammatory Syndrome 1 Protein,NACHT, LRR and PYD Domains-Containing Protein 3,NLRP3 Protein,NACHT, LRR and PYD Domains Containing Protein 3,NLR Family, Pyrin Domain Containing 3 Protein
D000080424 Cytokine Release Syndrome A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY. Cytokine Storm,Cytokine Storm Syndrome,Hypercytokinemia,Cytokine Release Syndromes,Cytokine Storms,Hypercytokinemias
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D020382 Interleukin-18 A cytokine which resembles IL-1 structurally and IL-12 functionally. It enhances the cytotoxic activity of NK CELLS and CYTOTOXIC T-LYMPHOCYTES, and appears to play a role both as neuroimmunomodulator and in the induction of mucosal immunity. IFN-gamma-Inducing Factor,IL-18,Interferon-gamma-Inducing Factor,IFN-gamma Inducing Factor,IL18,Interferon-gamma Inducing Factor,IFN gamma Inducing Factor,Inducing Factor, IFN-gamma,Inducing Factor, Interferon-gamma,Interferon gamma Inducing Factor,Interleukin 18

Related Publications

Pakorn Sagulkoo, and Kitiporn Plaimas, and Apichat Suratanee, and Andrea Name Colado Simão, and Edna Maria Vissoci Reiche, and Michael Maes
July 2020, Signal transduction and targeted therapy,
Pakorn Sagulkoo, and Kitiporn Plaimas, and Apichat Suratanee, and Andrea Name Colado Simão, and Edna Maria Vissoci Reiche, and Michael Maes
April 2021, Human immunology,
Pakorn Sagulkoo, and Kitiporn Plaimas, and Apichat Suratanee, and Andrea Name Colado Simão, and Edna Maria Vissoci Reiche, and Michael Maes
November 2020, Tanaffos,
Pakorn Sagulkoo, and Kitiporn Plaimas, and Apichat Suratanee, and Andrea Name Colado Simão, and Edna Maria Vissoci Reiche, and Michael Maes
January 2021, Genetics and molecular biology,
Pakorn Sagulkoo, and Kitiporn Plaimas, and Apichat Suratanee, and Andrea Name Colado Simão, and Edna Maria Vissoci Reiche, and Michael Maes
March 2021, Vaccines,
Pakorn Sagulkoo, and Kitiporn Plaimas, and Apichat Suratanee, and Andrea Name Colado Simão, and Edna Maria Vissoci Reiche, and Michael Maes
November 2020, Vaccines,
Pakorn Sagulkoo, and Kitiporn Plaimas, and Apichat Suratanee, and Andrea Name Colado Simão, and Edna Maria Vissoci Reiche, and Michael Maes
September 2021, Vaccines,
Pakorn Sagulkoo, and Kitiporn Plaimas, and Apichat Suratanee, and Andrea Name Colado Simão, and Edna Maria Vissoci Reiche, and Michael Maes
January 2022, International reviews of immunology,
Pakorn Sagulkoo, and Kitiporn Plaimas, and Apichat Suratanee, and Andrea Name Colado Simão, and Edna Maria Vissoci Reiche, and Michael Maes
July 2020, Clinical and experimental pediatrics,
Pakorn Sagulkoo, and Kitiporn Plaimas, and Apichat Suratanee, and Andrea Name Colado Simão, and Edna Maria Vissoci Reiche, and Michael Maes
January 2022, Medicina (Kaunas, Lithuania),
Copied contents to your clipboard!